COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants

As the SARS-CoV-2 pandemic evolves, new variants continue to emerge. Some highly transmissible variants, such as Delta, also raised concerns about the effectiveness provided by current vaccines. Understanding immunological correlates of protection and how laboratory findings correspond to clinical e...

Descripción completa

Detalles Bibliográficos
Autores principales: Cevik, Muge, Grubaugh, Nathan D., Iwasaki, Akiko, Openshaw, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445744/
https://www.ncbi.nlm.nih.gov/pubmed/34534444
http://dx.doi.org/10.1016/j.cell.2021.09.010
_version_ 1784568715382095872
author Cevik, Muge
Grubaugh, Nathan D.
Iwasaki, Akiko
Openshaw, Peter
author_facet Cevik, Muge
Grubaugh, Nathan D.
Iwasaki, Akiko
Openshaw, Peter
author_sort Cevik, Muge
collection PubMed
description As the SARS-CoV-2 pandemic evolves, new variants continue to emerge. Some highly transmissible variants, such as Delta, also raised concerns about the effectiveness provided by current vaccines. Understanding immunological correlates of protection and how laboratory findings correspond to clinical effectiveness is imperative to shape future vaccination strategies.
format Online
Article
Text
id pubmed-8445744
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-84457442021-09-17 COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants Cevik, Muge Grubaugh, Nathan D. Iwasaki, Akiko Openshaw, Peter Cell Commentary As the SARS-CoV-2 pandemic evolves, new variants continue to emerge. Some highly transmissible variants, such as Delta, also raised concerns about the effectiveness provided by current vaccines. Understanding immunological correlates of protection and how laboratory findings correspond to clinical effectiveness is imperative to shape future vaccination strategies. Elsevier Inc. 2021-09-30 2021-09-17 /pmc/articles/PMC8445744/ /pubmed/34534444 http://dx.doi.org/10.1016/j.cell.2021.09.010 Text en © 2021 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Commentary
Cevik, Muge
Grubaugh, Nathan D.
Iwasaki, Akiko
Openshaw, Peter
COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
title COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
title_full COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
title_fullStr COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
title_full_unstemmed COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
title_short COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
title_sort covid-19 vaccines: keeping pace with sars-cov-2 variants
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445744/
https://www.ncbi.nlm.nih.gov/pubmed/34534444
http://dx.doi.org/10.1016/j.cell.2021.09.010
work_keys_str_mv AT cevikmuge covid19vaccineskeepingpacewithsarscov2variants
AT grubaughnathand covid19vaccineskeepingpacewithsarscov2variants
AT iwasakiakiko covid19vaccineskeepingpacewithsarscov2variants
AT openshawpeter covid19vaccineskeepingpacewithsarscov2variants

Ejemplares similares